Bengaluru-based precision oncology startup 4baseCare has successfully raised Rs 128 crore ($13.3 million) in funding, reinforcing its position in the rapidly evolving cancer diagnostics sector. This fresh capital injection, which includes a top-up round of Rs 38 crore led by growX Ventures and Infosys, underscores the growing investor confidence in technology-driven healthcare solutions aimed at combating cancer. The funds will enable 4baseCare to expand its genomic laboratory network globally and enhance its AI-driven oncology platform, addressing the pressing need for advanced cancer diagnostics in underserved regions.
### The Company and Its Offerings
Founded in 2019 by Hitesh Goswami and Kshitij Rishi, 4baseCare specializes in developing genomics-based cancer diagnostics and AI-powered clinical decision support solutions. The company’s flagship platform, OncoTwin, leverages clinico-genomic and real-world patient data to provide oncologists with actionable treatment insights. Currently, 4baseCare operates laboratories in India, Dubai, Nepal, and the Philippines, and plans to extend its reach to an additional 8–10 countries within the next 12–18 months. The startup is also actively expanding its in-hospital genomics lab model through strategic partnerships with prominent healthcare institutions like AIIMS Jammu, Max Healthcare, and Shankara Hospital. With a current monthly output of around 1,500 genomic tests, the company anticipates scaling up to 8,000–10,000 tests per month as it broadens its operational footprint.
### Context and Competitive Landscape
The infusion of capital into 4baseCare comes amidst a burgeoning interest in cancer-focused startups within India and beyond. The precision oncology market is witnessing significant traction, with startups like Everhope Oncology, MOC Cancer Care & Research Centre, ErlySign, OnCare, and OneCell Diagnostics securing substantial funding in recent years. Everhope Oncology raised $10 million in a seed round, while MOC Cancer Care & Research Centre attracted $18 million led by Elevation Capital. These investments highlight the competitive yet promising landscape of oncology startups, where technological innovations are increasingly pivotal in driving advancements in cancer treatment and diagnostics.
### Implications for India’s Startup Ecosystem
4baseCare’s successful funding round is indicative of a broader trend within India’s startup ecosystem, where health tech solutions are gaining momentum. The company’s focus on leveraging genomics and AI to improve cancer diagnostics aligns with the growing emphasis on personalized medicine and precision healthcare. As India continues to emerge as a hub for healthcare innovation, startups like 4baseCare are poised to play a crucial role in transforming cancer treatment paradigms not only in India but also in other emerging markets. The startup’s expansion into international territories further exemplifies the global aspirations of Indian health tech companies, positioning them as key contributors to the global fight against cancer.
As 4baseCare embarks on its next phase of growth, industry stakeholders will be closely monitoring the startup’s ability to scale its operations effectively while maintaining the quality and precision of its diagnostic offerings. For founders and investors, the company’s trajectory will offer valuable insights into the scalability of genomics-based healthcare solutions, particularly in emerging markets. The next steps for 4baseCare will likely involve deepening its technological capabilities and forging new partnerships to sustain its growth momentum. As the company executes its expansion strategy, its progress will serve as a bellwether for the potential of precision oncology startups within the Indian and global healthcare landscapes.
